Bharat Biotech: Last News

Covid-19 vaccine: Japan approves Covaxin booster dose for travellers

Covaxin, Japan also recognizes Pfizer's Comirnaty, AstraZeneca's Vaxzevria, Moderna's Spikevax, Janssen's JCOVDEN, and Novavax's Nuvaxovid. Last month, the Hyderabad-based company announced that the administration of the third dose of its Covid-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination dramatically increased neutralizing antibody responses, and showed increased memory B cell response in subjects in controlled clinical trials.

The company said the findings are based on a comprehensive study that has demonstrated multiple benefits of Covaxin. According to Bharat Biotech, the vaccine provides benefits like long-term immune response, cell-mediated immunity, the safety of booster dose, and immunogenicity against spike protein.

Bharat Biotech said immune responses declined at six months but increased by 40-fold in subjects who received a booster dose. Immune responses when assessed against variants of concern and persisted up to 12 months.

The study was conducted on 184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, 6 months after the primary series of two doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, and N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity, said the company.

Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, "Our team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD, and N proteins. Post booster dose, it has proven to neutralize antibody responses against variants of concern and long-term protection through memory T and B cell

. covid-19 vaccine Immunic

Bharat Biotech

Related News